Credit: Michael S. Helfenbein, Yale University A seven-day, extended-release version of buprenorphine—a treatment for opioid use disorder (OUD) that can reduce opioid use and overdose deaths—is safe and effective for people with OUD experiencing minimal symptoms of withdrawal, a new Yale study finds. Individuals with minimal opioid withdrawal are often not prescribed the more common under-the-tongue, or sublingual, version of buprenorphine, in part because the treatment itself can induce sudden withdrawal. Withdrawal is measured through the Clinical Opioid Withdrawal Scale, which ranges from 0 to 48, and individuals were invited Read More